Hardman & Co Research: Redx Pharma (REDX): Streamlined, focused and good value

Hardman & Co: Streamlined, focused and good value

Redx Pharma (REDX) is a clinical-stage R&D company focused on drugs targeting oncology and fibrotic disease. 2018 was a year that reset the benchmarks - new management team, restructured organisation focused on two therapeutic areas, and a clean balance sheet with £6.5m cash. 2019 should be a busy year for the company, with several major milestones expected. RXC004, is due to re-start a Phase I/IIa trial for cancer with a revised formulation and dosing schedule. RXC006 has been nominated as the first development candidate in the anti-fibrotic programmes for progression to proof-of-concept trials.

Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/streamlined-focused-and-good-value/

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.